Key result
The age-standardised minimal point prevalence of genetic muscle disorders in New Zealand was 22.3 per 100,000 (95% CI 19.5-25.6), with prevalence in Europeans twice that of other ethnic groups.
Why the study?
Previous epidemiological studies of genetic muscle disorders relied on medical records and risked selection bias or focused on selective populations, leaving age-standardised nationwide prevalence unclear.
Population
Adults and children with a genetic muscle disorder resident in New Zealand on April 1, 2015
Design
Nationwide population-based cross-sectional epidemiological study using capture-recapture method
Authors
Loading...
May inform rare disease service planning; leaves open ethnic disparities and validation in other populations.
Cross-Sectional
Yes
The prevalence of genetic muscle disorders in New Zealand exhibits significant ethnic and regional variations, highlighting the need for tailored service delivery planning.
Theadom et al. (2019) conducted a cross-sectional in Genetic muscle disorders. Genetic muscle disorders was evaluated on Age-standardised minimal point prevalence per 100,000 persons (95% CI 19.5-25.6). The age-standardised minimal point prevalence of genetic muscle disorders in New Zealand was 22.3 per 100,000 (95% CI 19.5-25.6), with prevalence in Europeans twice that of other ethnic groups.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: